These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 32683062)

  • 1. Indoleamine 2,3-Dioxygenase-1 Expression in Adrenocortical Carcinoma.
    Tierney JF; Vogle A; Finnerty B; Zarnegar R; Ghai R; Gattuso P; Fahey TJ; Keutgen XM
    J Surg Res; 2020 Dec; 256():90-95. PubMed ID: 32683062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and Prognostic Relevance of PD-1, PD-L1, and CTLA-4 Immune Checkpoints in Adrenocortical Carcinoma.
    Landwehr LS; Altieri B; Sbiera I; Remde H; Kircher S; Olabe J; Sbiera S; Kroiss M; Fassnacht M
    J Clin Endocrinol Metab; 2024 Aug; 109(9):2325-2334. PubMed ID: 38415841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PD1 Effects on Tumor Microenvironment.
    Lang J; Capasso A; Jordan KR; French JD; Kar A; Bagby SM; Barbee J; Yacob BW; Head LS; Tompkins KD; Freed BM; Somerset H; Clark TJ; Pitts TM; Messersmith WA; Eckhardt SG; Wierman ME; Leong S; Kiseljak-Vassiliades K
    J Clin Endocrinol Metab; 2020 Jan; 105(1):26-42. PubMed ID: 31513709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma.
    Landwehr LS; Altieri B; Schreiner J; Sbiera I; Weigand I; Kroiss M; Fassnacht M; Sbiera S
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32474412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of programmed death ligand 1 and 2 in adrenocortical cancer tissues: An exploratory study.
    Tierney JF; Vogle A; Poirier J; Min IM; Finnerty B; Zarnegar R; Pappas SG; Scognamiglio T; Ghai R; Gattuso P; Fahey TJ; Keutgen XM
    Surgery; 2019 Jan; 165(1):196-201. PubMed ID: 30413322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased indoleamine 2,3-dioxygenase activity and expression in prostate cancer following targeted immunotherapy.
    Zahm CD; Johnson LE; McNeel DG
    Cancer Immunol Immunother; 2019 Oct; 68(10):1661-1669. PubMed ID: 31606777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis.
    Li F; Sun Y; Huang J; Xu W; Liu J; Yuan Z
    Cancer Med; 2019 Dec; 8(17):7330-7344. PubMed ID: 31631566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES).
    Mills AM; Peres LC; Meiss A; Ring KL; Modesitt SC; Abbott SE; Alberg AJ; Bandera EV; Barnholtz-Sloan J; Bondy ML; Cote ML; Funkhouser E; Moorman PG; Peters ES; Schwartz AG; Terry PD; Wallace K; Schildkraut JM
    Int J Gynecol Pathol; 2019 Mar; 38(2):157-170. PubMed ID: 29485423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adrenocortical Carcinoma Steroid Profiles:
    Muzzi JCD; Magno JM; Cardoso MA; de Moura J; Castro MAA; Figueiredo BC
    Front Endocrinol (Lausanne); 2021; 12():672319. PubMed ID: 34194394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of programmed cell death protein 1 (PD-1) and indoleamine 2,3-dioxygenase (IDO) in the tumor microenvironment and in tumor-draining lymph nodes of breast cancer.
    Ye Q; Wang C; Xian J; Zhang M; Cao Y; Cao Y
    Hum Pathol; 2018 May; 75():81-90. PubMed ID: 29447919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of immune microenvironment in gastrointestinal stromal tumours.
    Blakely AM; Matoso A; Patil PA; Taliano R; Machan JT; Miner TJ; Lombardo KA; Resnick MB; Wang LJ
    Histopathology; 2018 Feb; 72(3):405-413. PubMed ID: 28871595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognosis significance of indoleamine 2, 3-dioxygenase, programmed death ligand-1 and tumor-infiltrating immune cells in microenvironment of breast cancer.
    Wei L; Wu N; Wei F; Li F; Zhang Y; Liu J; Ren X
    Int Immunopharmacol; 2020 Jul; 84():106506. PubMed ID: 32330866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Significance of Program Death Ligand-1 and Indoleamine-2,3-Dioxygenase Expression in Colorectal Carcinoma.
    Hacking S; Vitkovski T; Jain S; Jin C; Chavarria H; Wu D; Nasim M
    Appl Immunohistochem Mol Morphol; 2021 Mar; 29(3):201-208. PubMed ID: 32842025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy.
    Vanderstraeten A; Luyten C; Verbist G; Tuyaerts S; Amant F
    Cancer Immunol Immunother; 2014 Jun; 63(6):545-57. PubMed ID: 24658839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression and prognostic values of PD-1, PD-L1 and IDO-1 in sinonasal malignant mucosal melanoma].
    Liu HQ; Zou BQ; Wang SY
    Zhonghua Bing Li Xue Za Zhi; 2017 Nov; 46(11):782-788. PubMed ID: 29136692
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma.
    Inaba T; Ino K; Kajiyama H; Yamamoto E; Shibata K; Nawa A; Nagasaka T; Akimoto H; Takikawa O; Kikkawa F
    Gynecol Oncol; 2009 Nov; 115(2):185-92. PubMed ID: 19665763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Gene Expression Profile Reveals CDK4 as Therapeutic Target for Selected Patients With Adrenocortical Carcinoma.
    Liang R; Weigand I; Lippert J; Kircher S; Altieri B; Steinhauer S; Hantel C; Rost S; Rosenwald A; Kroiss M; Fassnacht M; Sbiera S; Ronchi CL
    Front Endocrinol (Lausanne); 2020; 11():219. PubMed ID: 32373071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of PD-L1, PD-L2, and IDO1 on tumor cells and density of CD8-positive tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma according to histological subtype.
    Takada K; Toyokawa G; Kinoshita F; Jogo T; Kohashi K; Wakasu S; Ono Y; Tanaka K; Oba T; Osoegawa A; Tagawa T; Azuma K; Okamoto I; Shimokawa M; Oda Y; Mori M
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2639-2650. PubMed ID: 32405745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of FSCN1 and FOXM1 are associated with poor prognosis of adrenocortical carcinoma patients.
    Liang J; Liu Z; Wei X; Zhou L; Tang Y; Zhou C; Wu K; Zhang F; Zhang F; Lu Y; Zhu Y
    BMC Cancer; 2019 Nov; 19(1):1165. PubMed ID: 31783819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STING agonist and IDO inhibitor combination therapy inhibits tumor progression in murine models of colorectal cancer.
    Shi J; Liu C; Luo S; Cao T; Lin B; Zhou M; Zhang X; Wang S; Zheng T; Li X
    Cell Immunol; 2021 Aug; 366():104384. PubMed ID: 34182334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.